Drugs / FOSGEMCITABINE PALABENAMIDE
FOSGEMCITABINE PALABENAMIDE
also known as
NUC-1031 · Acelarin · BIO-1031 · CPF-31 · Fosgemcitabine palabenamide, p(rs)- · Gemictabine protide · NUC-1031, (S)-
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02351765 | Jan 2016 → Mar 2019 | ampulla of vater cancer, cholangiocarcinoma, gallbladder cancer | The Christie NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT02303912 | Nov 2014 → Jan 2017 | ovarian cancer | Imperial College Healthcare NHS Trust | Completed | No outcome recorded |
| Phase 1 | NCT01621854 | Oct 2012 → Jun 2015 | cancer | Imperial College London | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03146663 | Sep 2017 → Dec 2019 | ovarian cancer | NuCana plc | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03610100 | Dec 2015 → Sep 2020 | pancreatic acinar cell carcinoma | The Clatterbridge Cancer Centre NHS Foundation Trust | Suspended | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04163900 | Dec 2019 → Mar 2022 | biliary tract cancer | NuCana plc | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOSGEMCITABINE PALABENAMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3126004 ↗ |
| Known as | Acelarin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03610100 ↗ |
| Known as | BIO-1031 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3126004 ↗ |
| Known as | CPF-31 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3126004 ↗ |
| Known as | Fosgemcitabine palabenamide, p(rs)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL3126004 ↗ |
| Known as | Gemictabine protide | ChEMBL registry synonym — accepted as the source's own label CHEMBL3126004 ↗ |
| Known as | NUC-1031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03146663 ↗ |
| Known as | NUC-1031, (S)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL3126004 ↗ |
| Modality | Small molecule | “NUC-1031, a Nucleotide Analogue, in Patients With Advanced Solid Tumours.” NCT01621854 ↗ |
| Route | Intravenous | “administered IV weekly on days 1, 8, \& 15 (Schedule A) or twice weekly on days 1 \& 5, 8 \& 12, 15 \&19 (Schedule B)” NCT01621854 ↗ |